Designating September, in 2026 and in each succeeding year, as Pulmonary Fibrosis Awareness Month in Virginia.
House Joint Resolution 78 designates September 2026 and every succeeding year as Pulmonary Fibrosis Awareness Month in Virginia. The resolution is primarily commemorative and educational: it recognizes pulmonary fibrosis as a serious, often fatal lung-scarring disease with limited treatment options, highlights the role of lung transplantation for some patients, and notes the estimated number of diagnoses nationwide each year. It also acknowledges the contributions of Virginia health institutions, including Virginia Commonwealth University Health System, Inova Fairfax Medical Campus, and the University of Virginia Health System, in pulmonary fibrosis care and research.
The resolution directs the Clerk of the House of Delegates to transmit a copy to the Pulmonary Fibrosis Foundation and to post the designation on the General Assembly website. It does not create a regulatory program, funding mechanism, or new rights or obligations; instead, it formally adds Virginia to the list of states recognizing September as a month for public awareness, education, and support for research related to pulmonary fibrosis.
HJ78 has no direct effect on the Virginia Code or regulatory law. Its legal impact is limited to an official legislative designation of September as Pulmonary Fibrosis Awareness Month, along with administrative instructions to notify the Pulmonary Fibrosis Foundation and publish the designation online. The practical effect is symbolic and promotional, intended to raise public awareness, encourage research support, and recognize affected patients, caregivers, and medical institutions.
The sentiment around the resolution appears strongly supportive and noncontroversial. The bill passed both chambers and the text frames pulmonary fibrosis as a serious public health issue deserving recognition, awareness, and research attention. The references to Virginia medical centers and the national awareness month suggest broad institutional and public-health support rather than partisan debate.
No notable controversy is evident in the available record. There are no committee transcripts, recorded votes, or amendments indicating disagreement. Because the resolution is honorary and awareness-focused, any discussion would likely center on the value of public recognition and disease education rather than on policy tradeoffs, costs, or legal changes. No opposing viewpoints are reflected in the provided materials.